Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) CEO Nevan C. Elam purchased 12,302 shares of the firm's stock in a transaction dated Thursday, March 27th. The stock was acquired at an average cost of $2.85 per share, with a total value of $35,060.70. Following the completion of the acquisition, the chief executive officer now directly owns 224,119 shares in the company, valued at approximately $638,739.15. This trade represents a 5.81 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Rezolute Price Performance
Shares of Rezolute stock opened at $2.90 on Tuesday. Rezolute, Inc. has a 1-year low of $2.22 and a 1-year high of $6.19. The business's fifty day moving average price is $4.22 and its two-hundred day moving average price is $4.73. The company has a market capitalization of $175.55 million, a P/E ratio of -2.38 and a beta of 0.95.
Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. On average, research analysts expect that Rezolute, Inc. will post -0.93 earnings per share for the current fiscal year.
Institutional Trading of Rezolute
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. bought a new position in shares of Rezolute in the third quarter valued at approximately $42,000. Alpine Global Management LLC acquired a new stake in Rezolute in the fourth quarter worth approximately $54,000. MML Investors Services LLC acquired a new stake in Rezolute in the third quarter worth approximately $57,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Rezolute in the 3rd quarter worth $65,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Rezolute by 65.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock valued at $112,000 after buying an additional 9,000 shares during the period. 82.97% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of brokerages have commented on RZLT. Craig Hallum upgraded Rezolute to a "strong-buy" rating in a research note on Tuesday, February 4th. HC Wainwright restated a "buy" rating and set a $14.00 price objective on shares of Rezolute in a research report on Thursday, February 13th. Guggenheim reaffirmed a "buy" rating on shares of Rezolute in a research report on Monday, February 10th. Finally, JMP Securities boosted their price target on shares of Rezolute from $8.00 to $9.00 and gave the company a "market outperform" rating in a report on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Rezolute presently has an average rating of "Buy" and an average price target of $24.38.
Read Our Latest Stock Analysis on Rezolute
Rezolute Company Profile
(
Get Free Report)
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
